Clin Mol Hepatol Volume_18 Number_2 June 2012 HBV DNA level begins to rise, which may lead to serious liver dam- age. Conflicts of Interest The authors have no conflicts to disclose. REFERENCES 1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reacti- vation of hepatitis B virus replication in patients receiving cyto- toxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188. 2. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reac- tivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009;20:2013-2017. 3. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reac- tivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-262. 4. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepa- titis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749. 5. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220. 6. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010;38:58-61. 7. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroen- terol Hepatol 2010;25:864-871. 8. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094. 9. Perrillo RP. Acute flares in chronic hepatitis B: the natural and un- natural history of an immunologically mediated liver disease. Gas- troenterology 2001;120:1009-1022. 10. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepati- tis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-340. 11. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour ne- crosis factor (anti-TNF) therapy in patients with chronic viral infec- tions: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63(Suppl 2):ii18-ii24. 12. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986;83:1627-1631. 13. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepa- titis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009;36:2416-2420. 14. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic dis- eases. J Rheumatol 2010;37:346-350. 15. Lam KC, Lai CL, Trepo C, Wu PC. Deleterious effect of predniso- lone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981;304:380-386. 16. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992;16:13-18. 17. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactiva- tion in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003;44:759-766. 18. Biancone L, Del Vecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G. Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology 2002;122:593-594. 19. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus activation. Liver Int 2011;31(Suppl 1):104-110. 228 http://dx.doi.org/10.3350/cmh.2012.18.2.225 http://www.e-cmh.org